ReviewBiomedicines2015
Circulating MicroRNAs as Biomarkers and Mediators of Cell-Cell Communication in Cancer.
Review in Biomedicines, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Systematic Review and Meta-analysis of the Prognostic Significance of miRNAs in Melanoma Patients.Molecular diagnosis & therapy · 2018Pooled it
- Evaluation of micro-RNA in extracellular vesicles from blood of patients with prostate cancer.PloS one · 2021Article
- MicroRNA-940 as a Potential Serum Biomarker for Prostate Cancer.Frontiers in oncology · 2021Article
- MicroRNAs in endometriosis: biological function and emerging biomarker candidates†.Biology of reproduction · 2019Review
- Age- and sex-dependent changes in levels of circulating brain-enriched microRNAs during normal aging.Aging · 2018Article
- Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.International journal of molecular sciences · 2018Review
- miRNAexpression profile of retinal pigment epithelial cells under oxidative stress conditions.FEBS open bio · 2018Article
- Prevention of hormonal breast cancer by dietary jamun.Molecular nutrition & food research · 2016Article
- Inflamma-miRs in Aging and Breast Cancer: Are They Reliable Players?Frontiers in medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The realization of personalized medicine for cancer will rely not only on the development of new therapies, but on biomarkers that direct these therapies to the right patient. MicroRNA expression profiles in the primary tumor have been shown to differ between cancer patients and healthy individuals, suggesting they might make useful biomarkers. However, examination of microRNA expression in the primary tumor requires an invasive biopsy procedure. More recently, microRNAs have been shown to be released from the primary tumor into the circulation where they can be utilized as non-invasive biomarkers to diagnose patients, predict prognosis, or indicate therapeutic response. This review provides an overview of the current use of circulating microRNAs as biomarkers as well as recent findings on their role in regulating cell signaling interactions in the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.